lThe journal eClinicalMedicine, part of THE LANCET Discovery Science, has released a phase III clinical trial result on pegmolesatide for anemia patients on dialysis with chronic kidney disease (CKD)1.
lTo further investigate whether pegmolesatide offers additional benefits to CKD patients with anemia on dialysis, researchers conducted a post-hoc analysis of the aforementioned phase III study.
lThe post-hoc analysis results, released at the 2024 ASN annual meeting, confirmed that pegmolesatide injection is capable of achieving the goals of maintaining hemoglobin level more effectively than short-acting erythropoietins (EPOs), and is superior in terms of safety.
The 2024 American Society of Nephrology (ASN) Kidney Week conference was held at the San Diego Convention Center in the United States from October 23 to 27 local time. The post-hoc analysis results of the phase III study of Hansoh Pharma's self-developed Class 1 innovative drug, pegmolesatide (trade name: Saint Luolai) for treating anemia in patients with chronic kidney disease (CKD) on dialysis, were presented as poster form at the conference2.
The ASN Annual Meeting is the premier global nephrology conference, aiming to share and discuss the latest research advancements and cutting-edge topics in the field of kidney diseases. In 2024, the conference attracted more than 12,000 professionals from the renal field around the world3.
Pegmolesatide is a novel long-acting pegylated (PEG) erythropoietin mimetic peptide, approved by the National Medical Products Administration (NMPA) in June 2023 for the treatment of anemia caused by chronic kidney disease (CKD)4, and was included in the National Reimbursement Drug List (NRDL) of China in the same year.
A randomized, multicenter, open-label, non-inferiority phase Ⅲ trial of pegmolesatide for anemia in CKD dialysis patients was previously published in eClinicalMedicine，which confirmed the efficacy and safety of pegmolesatide in treating anemia in CKD dialysis patients，with patients achieving stable hemoglobin targets with just one subcutaneous injection per month.
The Phase III post-hoc analysis results of pegmolesatide treatment for anemia in CKD patients undergoing hemodialysis, released at this ASN annual meeting, further confirm that pegmolesatide is superior in maintaining hemoglobin target level compared to short-acting erythropoietins, with an improved safety profile. The detailed information is as follows:
Study Profile
Pegmolesatide for the Treatment of Anemia in Patients with CKD Undergoing Dialysis: Insights from a Randomized Active-Controlled Phase 3 Study
lOctober 24, 2024 | Location: Exhibit Hall, Convention Center
lAbstract Time: 10:00 AM - 12:00 PM
lCategory: Anemia and Iron Metabolism
l200 Anemia and Iron Metabolism
Authors
lChen, Jianghua, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
lZhou, Linghui, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
lGuo, Minghao, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China
lZheng, Hongguang, General Hospital of Northern Theater Command, Shenyang, Liaoning, China
lXie, Deqiong, Second People's Hospital of Yibin, Yibin, Sichuan, China
lHu, Zhizhen, Jiangsu Hansoh Pharmaceutical Co Ltd, Lianyungang, Jiangsu, China
lLuo, Weili, Jiangsu Hansoh Pharmaceutical Co Ltd, Lianyungang, Jiangsu, China
BACKGROUND
Pegmolesatide, a novel long-acting pegylated erythropoietin mimetic peptide, has proved comparable efficacy and safety with epoetin alfa based on a randomized, multicenter, open-label, non-inferiority phase 3 study (NCT03902691). This post-hoc analysis aims to explore further benefits of pegmolesatide for the treatment of anemia patients on dialysis.
METHODS
A total of 372 chronic kidney disease (CKD) patients undergoing dialysis were randomized (2:1) to receive pegmolesatide or epoetin alfa for 52 weeks. Post-hoc analysis was conducted to assess the proportions of patients across various hemoglobin (Hb) ranges during the efficacy evaluation period.
RESULTS
A larger proportion of patients on pegmolesatide achieved mean Hb≥11 g/dL compared to those on epoetin alfa (63.9% vs. 44.7%, P=0.0003). More patients receiving pegmolesatide maintained their Hb levels within the target ranges of 11-12 g/dL (35.2% vs. 22.8%, P=0.0164) and 11-13 g/dL (57.5% vs. 36.8%, P=0.0002) compared to those receiving epoetin alfa. In subgroups of baseline characteristics with age ≤65 yrs., primary hypertension, stage 5 CKD≥12 months, CRP≤11.5 mg/L, serum ferritin between 100-500 ng/mL, and transferrin saturation≥20%, pegmolesatide also showed greater effect in maintaining Hb levels between 11-12 g/dL (Figure). Similar findings were observed in these subgroups for the target range of 11-13 g/dL. The incidences of treatment related adverse events of particular interest, including hypertension (4.5% vs. 6.5%), hepatotoxicity (0.8% vs. 2.4%) and hyperkalaemia (2.4% vs. 4.0%), were numerically lower in the pegmolesatide group.
CONCLUSION
Pegmolesatide demonstrated a stronger likelihood of maintaining Hb levels within guideline-recommended ranges and potentially provided a more favorable safety profile compared to epoetin alfa.
Reference:
【1】Zhang P, et al. Pegmolesatide for the treatment of anemia in patients undergoing dialysis: a randomized clinical trial. EClinicalMedicine. 2023 Oct 28;65:102273.
【2】Chen Jianghua,et al.Pegmolesatide for the Treatment of Anemia in Patients with CKD Undergoing Dialysis: Insights from a Randomized Active-Controlled Phase 3 Study. ASN 2024. ABSTRACT: TH-PO888
【3】American Society of Nephrology （ASN）. https://www.asnonline.org/education/kidneyweek/
【4】国家药监局批准培莫沙肽注射液上市. https://www.nmpa.gov.cn/yaowen/ypjgyw/ypyw/20230630195113151.html（发布时间：2023-06-30）
Statements
Hansoh Pharma does not recommend the use of any unapproved drugs or indications. Medical info in this release is for informational and news reporting only, and is not for advertising purposes. Don't use it for health care or diagnosis.
Forward-Looking Statements
This press release is intended to provide information about Hansoh Pharmaceutical Group Co., Ltd. and its affiliates, including their subsidiaries (collectively referred to as the "Hansoh Pharma"). It does not constitute a disclosure of information about the Hansoh Pharma or any investment recommendations.
The information contained in this release may include forward-looking statements related to the Hansoh Pharma's business and product prospects, as well as its plans, beliefs, expectations, and strategies. These statements are predictions based on speculative assumptions and are not guarantees of future performance. They are subject to risks and uncertainties, such as scientific, commercial, political, economic, financial, legal factors as well as competitive environment and social conditions, many of which are beyond the Hansoh Pharma's control and difficult to predict, thus actual results may differ significantly from what is stated here, and past securities price trends should not be used as a guide for future market conditions. As such, investors should exercise caution when using this information to make investment decisions. Phrases such as "commit," "expect," "believe," "predict," "anticipate," "forecast," "intent," “project,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “guidance,” “possible,” “potential,” “pursue,” “likely,” and words and terms of similar terms substance used in connection with any discussion of future plans, actions or events indicate forward-looking statements.
The Hansoh Pharma does not commit to or guarantee the accuracy, timeliness, or completeness of forward-looking information and assumes no obligation to update or revise these forward-looking statements. Neither the Hansoh Pharma nor any of its directors, employees, or agents will be responsible for any forward-looking statements that prove to be inaccurate or unachievable and any losses or damages incurred by users due to reliance on the information provided herein, including but not limited to direct, incidental, indirect, or punitive damages.
All information in this press release is current as of the date of release. The Hansoh Pharma assumes no responsibility to update or revise this information in light of new developments, future events, or other circumstances, except as required by law. Additionally, the Hansoh Pharma reserve the right to make changes, corrections, or discontinuations to all or part of the content of this press release at any time without notice. For information specifically related to the listed company, investors are encouraged to refer to the announcements and financial reports of Hansoh Pharma (03692.HK).
